SOPHiA GENETICS SA (SOPH) Financials

SOPH

FY2025 annual

Revenue $77.3M +18.6% YoY

Net Income -$79.0M -26.4% YoY

Free Cash Flow -$36.5M +18.5% YoY

Operating Cash Flow -$35.9M +19.4% YoY

Market Cap $628.2M as of Oct 6, 2026

Price / Sales 8.1x on $77.3M revenue, FY2025

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 13.3x on $47.1M equity, Q4 FY2025

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 6, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period FY2025, ended Dec 31, 2025 Reported Mar 3, 2026 Currency USD FYE December

Newest figures come from the 20-F for FY2025, filed Mar 3, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SOPH SEC filings page.

SOPHiA GENETICS SA (SOPH) reported $77.3M in revenue for fiscal year 2025, up 18.6% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SOPH FY2025 2026-10-04

Revenue is expanding, but operating losses remain larger than sales, leaving growth dependent on external financing.

FY2025 revenue reached $77.3M, while the net loss returned to $79.0M after narrowing in FY2024; that disconnect says scale has not yet converted into earnings. Operating cash flow improved to -$35.9M and free cash flow to -$36.5M, so cash consumption eased even as reported profitability deteriorated—an earnings-quality split that points to lower cash losses, not a self-funding model.

Total liabilities nearly doubled to $115.9M in FY2025 from $58.8M in FY2024, shifting more financing onto creditors. Equity fell to $47.1M, so the same operating losses now sit against a smaller balance-sheet base.

The current ratio fell from 3.7x to 2.0x, leaving less short-term asset coverage per unit of current liabilities. Capital expenditures were only $574K in FY2025, while free cash flow remained negative at -$36.5M; the cash drain therefore appears driven mainly by ongoing operations rather than heavy reinvestment.

Financial Health Signals

Financial health score not available

SOPHiA GENETICS SA does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

3/8

SOPHiA GENETICS SA passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

SOPHiA GENETICS SA reported a net loss of $79.0M while operations used $35.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

None of these metrics is reported for Q4 2025.

Cash & Balance Sheet

Cash & Debt

$70.3M

YoY-12.4%

QoQ-25.9%

SOPHiA GENETICS SA held $70.3M in cash against $12.6M in long-term debt as of Q4 2025.

Shares Outstanding

68M

YoY+2.7%

SOPHiA GENETICS SA had 68M shares outstanding in Q4 2025. This represents an increase of 2.7% from the same quarter a year earlier.

Free Cash Flow

Not reported for Q4 2025.

Dividends Per Share

Not reported for Q4 2025.

Margins & Returns

None of these metrics is reported for Q4 2025.

Capital Allocation

None of these metrics is reported for Q4 2025.

SOPH Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SOPH quarterly income statement

Metric	FY2520-F	FY2420-F	FY2320-F	FY2210-K	FY2110-K	FY2010-K	FY1910-K
Revenue	$77.3M+18.6%	$65.2M+4.5%	$62.4M+31.1%	$47.6M+17.6%	$40.5M+42.4%	$28.4M+12.0%	$25.4M
Interest Expense	$4.6M+138.1%	$1.9M+225.3%	$588K-8.0%	$639K-2.9%	$658K-21.7%	$840K-13.9%	$976K
Income Tax	$1.5M+23.6%	$1.2M+151.6%	$486K+457.4%	-$136K-181.0%	$168K+108.9%	-$1.9M-1264.2%	$162K
Net Income	-$79.0M-26.4%	-$62.5M+20.9%	-$79.0M+9.7%	-$87.4M-18.7%	-$73.7M-87.3%	-$39.3M-16.4%	-$33.8M
Diluted Shares (Avg)	68M+2.2%	66M+2.0%	65M+1.0%	64M+15.9%	55M+30.6%	42M	N/A

Metric	Q4'2520-F	Q2'256-K	Q4'2420-F	Q2'246-K	Q4'2310-K	Q2'2310-Q	Q4'2210-K	Q2'2210-Q
Revenue	N/A	$18.3M+15.9%	N/A	$15.8M+5.0%	N/A	$15.1M+29.0%	N/A	$11.7M
Interest Expense	N/A	$559K+11.6%	N/A	$501K+139.3%	N/A	-$1.3M-109.9%	N/A	-$608K
Income Tax	N/A	$762K+373.3%	N/A	$161K+120.5%	N/A	$73K+1316.7%	N/A	-$6K
Net Income	N/A	-$22.4M-47.5%	N/A	-$15.2M+29.0%	N/A	-$21.4M+13.3%	N/A	-$24.7M
Diluted Shares (Avg)	N/A	67M+2.1%	N/A	66M+2.2%	N/A	64M+0.6%	N/A	64M

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, EPS (Basic), EPS (Diluted).

SOPH Balance Sheet

SOPH quarterly balance sheet

Metric	FY2520-F	FY2420-F	FY2320-F	FY2210-K	FY2110-K	FY2010-K	FY1910-K
Total Assets	$163.0M+5.0%	$155.3M-24.7%	$206.2M-15.5%	$243.8M-23.8%	$320.2M+142.3%	$132.1M	N/A
Current Assets	$99.1M-0.3%	$99.4M-32.9%	$148.0M-24.6%	$196.3M-30.6%	$282.9M+157.9%	$109.7M	N/A
Cash & Equivalents	$70.3M-12.4%	$80.2M-34.9%	$123.3M-23.6%	$161.3M-16.4%	$193.0M+158.6%	$74.6M+313.0%	$18.1M
Inventory	$6.4M+8.2%	$5.9M-9.5%	$6.5M+25.7%	$5.2M-10.0%	$5.7M+69.3%	$3.4M	N/A
Accounts Receivable	$15.0M+101.7%	$7.4M-45.2%	$13.6M+103.9%	$6.6M+5.9%	$6.3M-1.3%	$6.4M	N/A
Goodwill	$35.9M+23.8%	$29.0M+6.7%	$27.2M+36.2%	$20.0M+27.4%	$15.7M+18.0%	$13.3M	N/A
Total Liabilities	$115.9M+97.0%	$58.8M+7.5%	$54.7M+25.2%	$43.7M-2.4%	$44.8M+41.7%	$31.6M	N/A
Current Liabilities	$50.5M+88.5%	$26.8M-24.8%	$35.6M+32.9%	$26.8M-6.3%	$28.6M+32.5%	$21.6M	N/A
Non-Current Liabilities	$65.4M+104.1%	$32.0M+67.7%	$19.1M+13.0%	$16.9M+4.5%	$16.2M+61.4%	$10.0M	N/A
Long-Term Debt	$12.6M-13.8%	$14.6M-6.8%	$15.7M+11.5%	$14.1M+25.0%	$11.2M+290.1%	$2.9M-24.9%	$3.8M
Total Equity	$47.1M-51.1%	$96.5M-36.3%	$151.4M-24.3%	$200.1M-27.3%	$275.4M+174.0%	$100.5M+351.7%	$22.3M
Retained Earnings	-$519.3M-17.9%	-$440.3M-16.5%	-$377.8M-26.4%	-$298.8M-41.4%	-$211.4M-53.5%	-$137.7M	N/A

Metric	Q4'2520-F	Q2'256-K	Q4'2420-F	Q2'246-K	Q4'2310-K	Q2'2310-Q	Q4'2210-K	Q2'2210-Q
Total Assets	$163.0M+5.0%	$177.6M-1.9%	$155.3M-24.7%	$181.1M-18.9%	$206.2M-15.5%	$223.2M	$243.8M-23.8%	N/A
Current Assets	$99.1M-0.3%	$117.0M-6.9%	$99.4M-32.9%	$125.8M-25.4%	$148.0M-24.6%	$168.6M	$196.3M-30.6%	N/A
Cash & Equivalents	$70.3M-12.4%	$94.8M-10.0%	$80.2M-34.9%	$105.4M-29.1%	$123.3M-23.6%	$148.6M-17.0%	$161.3M-16.4%	$178.9M
Inventory	$6.4M+8.2%	$6.2M-5.0%	$5.9M-9.5%	$6.5M+19.9%	$6.5M+25.7%	$5.5M	$5.2M-10.0%	N/A
Accounts Receivable	$15.0M+101.7%	$9.5M-4.2%	$7.4M-45.2%	$9.9M+0.8%	$13.6M+103.9%	$9.8M	$6.6M+5.9%	N/A
Goodwill	$35.9M+23.8%	N/A	$29.0M+6.7%	N/A	$27.2M+36.2%	N/A	$20.0M+27.4%	N/A
Total Liabilities	$115.9M+97.0%	$100.9M+69.2%	$58.8M+7.5%	$59.7M+15.8%	$54.7M+25.2%	$51.5M	$43.7M-2.4%	N/A
Current Liabilities	$50.5M+88.5%	$34.5M+20.5%	$26.8M-24.8%	$28.6M-9.3%	$35.6M+32.9%	$31.5M	$26.8M-6.3%	N/A
Non-Current Liabilities	$65.4M+104.1%	$66.4M+114.0%	$32.0M+67.7%	$31.0M+55.6%	$19.1M+13.0%	$20.0M	$16.9M+4.5%	N/A
Long-Term Debt	$12.6M-13.8%	$13.9M-2.1%	$14.6M-6.8%	$14.2M-13.5%	$15.7M+11.5%	$16.4M	$14.1M+25.0%	N/A
Total Equity	$47.1M-51.1%	$76.7M-36.8%	$96.5M-36.3%	$121.4M-29.3%	$151.4M-24.3%	$171.7M-24.7%	$200.1M-27.3%	$228.1M
Retained Earnings	-$519.3M-17.9%	-$480.1M-18.0%	-$440.3M-16.5%	-$406.7M-19.6%	-$377.8M-26.4%	-$339.9M	-$298.8M-41.4%	N/A

Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments.

SOPH Cash Flow Statement

SOPH quarterly cash flow statement

Metric	FY2520-F	FY2420-F	FY2320-F	FY2210-K	FY2110-K	FY2010-K	FY1910-K
Operating Cash Flow	-$35.9M+19.4%	-$44.5M+16.4%	-$53.2M+24.1%	-$70.1M-21.0%	-$57.9M-82.6%	-$31.7M-0.2%	-$31.7M
Capital Expenditures	$574K+135.2%	$244K-83.7%	$1.5M-63.5%	$4.1M+52.7%	$2.7M+496.2%	$450K-66.8%	$1.4M
Free Cash Flow	-$36.5M+18.5%	-$44.8M+18.2%	-$54.7M+26.2%	-$74.2M-22.4%	-$60.6M-88.4%	-$32.2M+2.6%	-$33.0M
Investing Cash Flow	-$8.7M-82.3%	-$4.8M-136.6%	$13.0M-69.1%	$42.0M+173.7%	-$56.9M-134.1%	-$24.3M-701.9%	-$3.0M
Financing Cash Flow	$30.2M+206.1%	$9.9M+449.2%	-$2.8M-80.0%	-$1.6M-100.7%	$237.8M+122.1%	$107.0M+10563.8%	-$1.0M

Metric	Q4'2520-F	Q2'256-K	Q4'2420-F	Q2'246-K	Q4'2310-K	Q2'2310-Q	Q4'2210-K	Q2'2210-Q

Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.

SOPH Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SOPH quarterly financial ratios

Metric	FY2520-F	FY2420-F	FY2320-F	FY2210-K	FY2110-K	FY2010-K	FY1910-K
Net Margin	-102.2%	-95.9%	-126.6%	-183.9%	-182.1%	-138.5%	-133.2%
Return on Equity	-167.6%-102.8pp	-64.8%-12.6pp	-52.1%-8.4pp	-43.7%-16.9pp	-26.8%+12.4pp	-39.1%+112.7pp	-151.8%
Return on Assets	-48.5%-8.2pp	-40.2%-1.9pp	-38.3%-2.5pp	-35.9%-12.8pp	-23.0%+6.8pp	-29.8%	N/A
Current Ratio	1.96-1.7x	3.71-0.4x	4.16-3.2x	7.32-2.6x	9.89+4.8x	5.08	N/A
Debt-to-Equity	0.27+0.1x	0.150.0x	0.100.0x	0.070.0x	0.040.0x	0.03-0.1x	0.17
Asset Turnover	0.47+0.1x	0.42+0.1x	0.30+0.1x	0.20+0.1x	0.13-0.1x	0.21	N/A
FCF Margin	-47.2%+21.5pp	-68.7%+19.1pp	-87.7%	-156.0%	-149.9%	-113.3%	-130.3%

Metric	Q4'2520-F	Q2'256-K	Q4'2420-F	Q2'246-K	Q4'2310-K	Q2'2310-Q	Q4'2210-K	Q2'2210-Q
Net Margin	N/A	-122.3%	N/A	-96.1%	N/A	-142.1%	N/A	-211.5%
Return on Equity	N/A	-29.2%-16.7pp	N/A	-12.5%0.0pp	N/A	-12.5%-1.6pp	N/A	-10.8%
Return on Assets	N/A	-12.6%-4.2pp	N/A	-8.4%+1.2pp	N/A	-9.6%	N/A	N/A
Current Ratio	1.96-1.7x	3.39-1.0x	3.71-0.4x	4.40-0.9x	4.16-3.2x	5.34	7.32-2.6x	N/A
Debt-to-Equity	0.27+0.1x	0.18+0.1x	0.150.0x	0.120.0x	0.100.0x	0.10	0.070.0x	N/A
Asset Turnover	N/A	0.100.0x	N/A	0.090.0x	N/A	0.07	N/A	N/A

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
SOPHiA GENETICS SA SOPH	FY2025	$77.3M	-$79.0M	N/A	$628.2M	—
Health Catalyst, Inc HCAT	FY2025	$311.1M	-$178.0M	-57.2%	$131.7M	38/100
Mobile-health Network Solutions MNDR	FY2025	$7.6M	-$3.4M	-44.3%	$1.6M	20/100
LifeMD, Inc. LFMD	FY2025	$194.1M	-$11.2M	-5.8%	$132.2M	41/100
CareCloud, Inc. CCLD	FY2025	$120.5M	$11K	0.0%	$85.8M	46/100
Simulations Plus, Inc. SLP	FY2025	$79.2M	-$64.7M	-81.7%	$374.2M	61/100

Where SOPHiA GENETICS SA Ranks

Frequently Asked Questions

What is SOPHiA GENETICS SA's annual revenue?

SOPHiA GENETICS SA (SOPH) reported $77.3M in total revenue for fiscal year 2025. This represents a 18.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is SOPHiA GENETICS SA's revenue growing?

SOPHiA GENETICS SA (SOPH) revenue grew by 18.6% year-over-year, from $65.2M to $77.3M in fiscal year 2025.

Is SOPHiA GENETICS SA profitable?

No, SOPHiA GENETICS SA (SOPH) reported a net income of -$79.0M in fiscal year 2025.

How much debt does SOPHiA GENETICS SA have?

As of fiscal year 2025, SOPHiA GENETICS SA (SOPH) had $70.3M in cash and equivalents against $12.6M in long-term debt.

What is SOPHiA GENETICS SA's return on equity (ROE)?

SOPHiA GENETICS SA (SOPH) has a return on equity of -167.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is SOPHiA GENETICS SA's free cash flow?

SOPHiA GENETICS SA (SOPH) recorded an outflow of $36.5M in free cash flow during fiscal year 2025. This represents a 18.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is SOPHiA GENETICS SA's operating cash flow?

SOPHiA GENETICS SA (SOPH) recorded an outflow of $35.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are SOPHiA GENETICS SA's total assets?

SOPHiA GENETICS SA (SOPH) had $163.0M in total assets as of fiscal year 2025, including both current and long-term assets.

What are SOPHiA GENETICS SA's capital expenditures?

SOPHiA GENETICS SA (SOPH) invested $574K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does SOPHiA GENETICS SA have outstanding?

SOPHiA GENETICS SA (SOPH) had 68M shares outstanding as of fiscal year 2025.

What is SOPHiA GENETICS SA's current ratio?

SOPHiA GENETICS SA (SOPH) had a current ratio of 1.96 as of fiscal year 2025, which is generally considered healthy.

What is SOPHiA GENETICS SA's debt-to-equity ratio?

SOPHiA GENETICS SA (SOPH) had a debt-to-equity ratio of 0.27 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is SOPHiA GENETICS SA's return on assets (ROA)?

SOPHiA GENETICS SA (SOPH) had a return on assets of -48.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is SOPHiA GENETICS SA's P/E ratio?

SOPHiA GENETICS SA (SOPH) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $628.2M as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is SOPHiA GENETICS SA's price-to-sales ratio?

SOPHiA GENETICS SA (SOPH) trades at 8.1x sales, its market capitalization divided by revenue of $77.3M revenue, FY2025. The market capitalization is $628.2M as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is SOPHiA GENETICS SA's Piotroski F-Score?

SOPHiA GENETICS SA (SOPH) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are SOPHiA GENETICS SA's earnings high quality?

SOPHiA GENETICS SA (SOPH) reported a net loss of $79.0M while operations used $35.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.